Select publications
De Gramont A et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(Suppl 11):42-5. Abstract
Hochster HS. Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006;33(5 Suppl 10):8-14. Abstract
Hoff PM. Bevacizumab in older patients and patients with poorer performance status. Semin Oncol 2006;33(5 Suppl 10):19-25. Abstract
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Sargent DJ et al. A pooled safety and efficacy analysis of the FOLFOX4 regimen (bimonthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer. Proc ASCO 2006;Abstract 3517.
Vincenzi B et al. The new era in the treatment of advanced colorectal cancer patients: The role of monoclonal antibodies. Expert Opin Emerg Drugs 2006;11(4):665-83. Abstract
Willett CG et al. Combined vascular endothelial growth factor-targeted therapy and
radiotherapy for rectal cancer: Theory and clinical practice. Semin Oncol 2006;33(5 Suppl 10):35-40. Abstract
Willett CG et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-9. No abstract available
Willett CG et al. Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7. Abstract
